RxDoctor Payments Data

Jenna Rickenbaugh, NP

Nurse Practitioner · Newburgh, INNPI 1841809696

Payments from drug & device makers

$6,626in general payments, 2019–2025

Across 442 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$847
  • GSK$399
  • Lilly USA, LLC$399
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$383
  • Otsuka America Pharmaceutical, Inc.$268
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$6,626100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,626 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$25,643
Medicare patients
119
Services billed
378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$49,993
MounjaroTirzepatide17$21,812
EliquisApixaban21$21,706
TrulicityDulaglutide18$19,314
VraylarCariprazine Hcl11$17,372
FarxigaDapagliflozin Propanediol11$8,588
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen51$2,273
Potassium Chloride45$1,143
Omeprazole93$1,035
SynthroidLevothyroxine Sodium14$1,007
Levothyroxine Sodium154$839
Albuterol Sulfate HfaAlbuterol Sulfate33$817
Gabapentin50$748
Fenofibrate29$610
Atorvastatin Calcium129$550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$847$49,99333 claims
Lilly USA, LLCMounjaro, Trulicity$399$41,12635 claims
PfizerEliquis$209$21,70621 claims
AbbVieVraylar, Synthroid$2,137$18,37925 claims
AstraZenecaFarxiga$103$8,58811 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$839154 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Newburgh

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →